Cargando…

细胞间邻近标记技术在慢性髓性白血病中的应用及其临床意义

OBJECTIVE: This study aimed to explore the application of interaction-dependent fucosyl-biotinylation(FucoID), a chemical biology-based proximity labeling technique, in capturing tumor antigen-specific T cells and its clinical value in chronic myelogenous leukemia(CML). METHODS: Flow cytometry and f...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509616/
https://www.ncbi.nlm.nih.gov/pubmed/37749032
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.07.003
_version_ 1785107772482781184
collection PubMed
description OBJECTIVE: This study aimed to explore the application of interaction-dependent fucosyl-biotinylation(FucoID), a chemical biology-based proximity labeling technique, in capturing tumor antigen-specific T cells and its clinical value in chronic myelogenous leukemia(CML). METHODS: Flow cytometry and fluorescence microscopy were employed to evaluate the experimental parameters for FucoID in CML. Peripheral blood samples were obtained from 14 newly diagnosed CML patients in the chronic phase. These samples underwent flow cytometry-based sorting and were subsequently labeled with FucoID to facilitate the isolation of tumor cells and T cells, followed by the immunophenotypic identification of tumor antigen-specific T cells. Finally, the diagnostic and therapeutic potential of FucoID in CML was assessed. RESULTS: Initially, the experimental parameters for FucoID in CML were established. The proportion of CD3(+) T cells in patients was(8.96±6.47)%, exhibiting a marked decrease compared with that in healthy individuals at(38.89±22.62)%. The proportion of tumor-specific antigen-reactive T cells was(3.34±4.49)%, which demonstrated interpatient variability. In addition, the proportion of tumor-specific antigen-active T cells in CD4(+) T cells was(3.95±1.72)%, which was generally lower than the proportion in CD8(+) T cells at(5.68±2.18)%. Compared with those in tumor-specific antigen-nonreactive T cells, CCR7(−)CD45RA(−) effector memory T cells and CCR7(−)CD45RA(+) effector T cells were highly enriched in tumor-specific antigen-reactive T cells. Moreover, the intensity of tumor immune reactivity in patients exhibited a significant correlation with white blood cell count(WBC)and hemoglobin(HGB)levels in peripheral blood, while no such correlation was observed with other clinical baseline characteristics. CONCLUSION: The combination of FucoID and flow cytometry enables the rapid identification and isolation of tumor antigen-specific T cells in CML. The successful application of this method in CML and the implications of our findings suggest its potential clinical value in the field of hematologic malignancies.
format Online
Article
Text
id pubmed-10509616
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-105096162023-09-21 细胞间邻近标记技术在慢性髓性白血病中的应用及其临床意义 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: This study aimed to explore the application of interaction-dependent fucosyl-biotinylation(FucoID), a chemical biology-based proximity labeling technique, in capturing tumor antigen-specific T cells and its clinical value in chronic myelogenous leukemia(CML). METHODS: Flow cytometry and fluorescence microscopy were employed to evaluate the experimental parameters for FucoID in CML. Peripheral blood samples were obtained from 14 newly diagnosed CML patients in the chronic phase. These samples underwent flow cytometry-based sorting and were subsequently labeled with FucoID to facilitate the isolation of tumor cells and T cells, followed by the immunophenotypic identification of tumor antigen-specific T cells. Finally, the diagnostic and therapeutic potential of FucoID in CML was assessed. RESULTS: Initially, the experimental parameters for FucoID in CML were established. The proportion of CD3(+) T cells in patients was(8.96±6.47)%, exhibiting a marked decrease compared with that in healthy individuals at(38.89±22.62)%. The proportion of tumor-specific antigen-reactive T cells was(3.34±4.49)%, which demonstrated interpatient variability. In addition, the proportion of tumor-specific antigen-active T cells in CD4(+) T cells was(3.95±1.72)%, which was generally lower than the proportion in CD8(+) T cells at(5.68±2.18)%. Compared with those in tumor-specific antigen-nonreactive T cells, CCR7(−)CD45RA(−) effector memory T cells and CCR7(−)CD45RA(+) effector T cells were highly enriched in tumor-specific antigen-reactive T cells. Moreover, the intensity of tumor immune reactivity in patients exhibited a significant correlation with white blood cell count(WBC)and hemoglobin(HGB)levels in peripheral blood, while no such correlation was observed with other clinical baseline characteristics. CONCLUSION: The combination of FucoID and flow cytometry enables the rapid identification and isolation of tumor antigen-specific T cells in CML. The successful application of this method in CML and the implications of our findings suggest its potential clinical value in the field of hematologic malignancies. Editorial office of Chinese Journal of Hematology 2023-07 /pmc/articles/PMC10509616/ /pubmed/37749032 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.07.003 Text en 2023年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License.
spellingShingle 论著
细胞间邻近标记技术在慢性髓性白血病中的应用及其临床意义
title 细胞间邻近标记技术在慢性髓性白血病中的应用及其临床意义
title_full 细胞间邻近标记技术在慢性髓性白血病中的应用及其临床意义
title_fullStr 细胞间邻近标记技术在慢性髓性白血病中的应用及其临床意义
title_full_unstemmed 细胞间邻近标记技术在慢性髓性白血病中的应用及其临床意义
title_short 细胞间邻近标记技术在慢性髓性白血病中的应用及其临床意义
title_sort 细胞间邻近标记技术在慢性髓性白血病中的应用及其临床意义
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509616/
https://www.ncbi.nlm.nih.gov/pubmed/37749032
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.07.003
work_keys_str_mv AT xìbāojiānlínjìnbiāojìjìshùzàimànxìngsuǐxìngbáixuèbìngzhōngdeyīngyòngjíqílínchuángyìyì
AT xìbāojiānlínjìnbiāojìjìshùzàimànxìngsuǐxìngbáixuèbìngzhōngdeyīngyòngjíqílínchuángyìyì
AT xìbāojiānlínjìnbiāojìjìshùzàimànxìngsuǐxìngbáixuèbìngzhōngdeyīngyòngjíqílínchuángyìyì
AT xìbāojiānlínjìnbiāojìjìshùzàimànxìngsuǐxìngbáixuèbìngzhōngdeyīngyòngjíqílínchuángyìyì
AT xìbāojiānlínjìnbiāojìjìshùzàimànxìngsuǐxìngbáixuèbìngzhōngdeyīngyòngjíqílínchuángyìyì
AT xìbāojiānlínjìnbiāojìjìshùzàimànxìngsuǐxìngbáixuèbìngzhōngdeyīngyòngjíqílínchuángyìyì
AT xìbāojiānlínjìnbiāojìjìshùzàimànxìngsuǐxìngbáixuèbìngzhōngdeyīngyòngjíqílínchuángyìyì